Dr. Reddy's Laboratories launched Zytorvi (Toripalimab), a novel immunotherapy drug for recurrent or metastatic nasopharyngeal carcinoma (NPC), a rare head and neck cancer. This marks India as the third country globally with access to this next-gen PD-1 inhibitor, offering a superior treatment alternative to standard chemotherapy. Dr. Read The Rest at :
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.
